Brainfish, the cutting-edge AI platform revolutionizing product adoption, is thrilled to announce that it has successfully raised $3,000,000 in its latest funding round. This significant investment underscores the growing demand for innovative solutions that enhance user engagement and facilitate a seamless product experience. Brainfish’s robust suite of models and easy-to-integrate UI empower businesses to activate, train, and retain users effectively, ensuring that all users can navigate the complexities of new technologies with ease. With this new capital, Brainfish plans to accelerate the development of its platform, enhancing its capabilities to deliver personalized self-service workflows and deeper analytical insights. These advancements will not only support users in maximizing their product experience but also provide companies with a clearer view of user behaviors and needs throughout the product journey. The funding will also be allocated towards expanding the team and further refining the user interface, making the integration process even more straightforward and efficient. This new funding round is a significant step towards empowering businesses to optimize their user adoption strategies and capitalize on the full potential of their products, ultimately driving better outcomes and greater customer satisfaction. As the landscape of product adoption continues to evolve, Brainfish is poised to lead the charge, helping companies turn casual users into loyal advocates through the power of AI-driven insights and automation.
Brainfish Secures $3 Million in Seed Funding for Revolutionary AI Product Adoption Platform
Recently funded · $3.0M SeedTechnology/Artificial Intelligence
Get the full Brainfish company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Mach42
Mach42â„¢ is a spinout company from Oxford University, delivering the next step-change in simulation acceleration, an early-stage software company developing state-of-the-art machine learning and Artificial Intelligence technology to simplify, automate, and accelerate simulation tasks. We leverage proprietary neural network technology to accelerate expensive calculations, and we do it with minimal data and high accuracy, providing many orders of magnitude speedup in verification acceleration. Our platform is already delivering a substantial competitive advantage to our early customers.
$9.1M Seed
today
Transcripta Bio
We are focused on drug discovery at unprecedented speed and scale, with lower risk and higher certainty across multiple diseases in parallel. With data from hundreds of millions of experiments, we have mapped the effects of thousands of compounds on gene expression to discover new therapies. Our Drug-Gene Atlas maps molecular structure and drug action to the whole cell transcriptome, revealing therapeutic candidates that rebalance gene expression to treat disease. Our proprietary artificial intelligence modeling suite, Conductor AI, used our Drug-Gene Atlas to discover and predict the effects of new drugs at transcriptome scale.
Other recent Seed rounds
Companies that recently closed a Seed round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | Mach42 United States | Seed | $9.1M | today |
| 2 |  1872 United States | Seed | $15.0M | today |
| 3 |
